(Li et al., 2021; Zelniker et al., 2019) Large cardiovascular outcome trials have demonstrated that SGLT2 inhibitors significantly reduce risks of heart failure hospitalization, progression of kidney disease, and even major adverse cardiovascular events (MACE) and mortality in patients with T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.